

Review

The “www” of *Xenopus laevis* Oocytes: The Why, When, What of *Xenopus laevis* Oocytes in Membrane Transporters Research

Manan Bhatt ^{1,2,†}, Angela Di Iacovo ^{1,2,†}, Tiziana Romanazzi ^{1,2,†}, Cristina Roseti ^{1,3}, Raffaella Cinquetti ¹ and Elena Bossi ^{1,3,*}

¹ Laboratory of Cellular and Molecular Physiology, Department of Biotechnology and Life Sciences, university of Insubria, via Dunant 3, I-21100 Varese, Italy

² Experimental and translational Medicine, University of Insubria, Via Ottorino Rossi 9, 21100 Varese, Italy

³ Centre for Neuroscience—Via Manara 7, University of Insubria, 21052 Busto Arsizio, Italy

* Correspondence: elena.bossi@uninsubria.it

† These authors equally contributed to this work.

Abstract: After 50 years, the heterologous expression of proteins in *Xenopus laevis* oocytes is still essential in many research fields. New approaches and revised protocols, but also classical methods, such as the two-electrode voltage clamp, are applied in studying membrane transporters. New and old methods for investigating the activity and the expression of Solute Carriers (SLC) are reviewed, and the kinds of experiment that are still useful to perform with this kind of cell are reported. *Xenopus laevis* oocytes at the full-grown stage have a highly efficient biosynthetic apparatus that correctly targets functional proteins at the defined compartment. This small protein factory can produce, fold, and localize almost any kind of wild-type or recombinant protein; some tricks are required to obtain high expression and to verify the functionality. The methodologies examined here are mainly related to research in the field of membrane transporters. This work is certainly not exhaustive; it has been carried out to be helpful to researchers who want to quickly find suggestions and detailed indications when investigating the functionality and expression of the different members of the solute carrier families.

Keywords: *Xenopus* oocyte; solute carrier; two-electrode voltage clamp; fluorophores; RNA microinjection; membrane transplantation; membrane transporter; immunochemistry; single-oocyte chemiluminescence

Citation: Bhatt, M.; Di Iacovo, A.; Romanazzi, T.; Roseti, C.; Cinquetti, R.; Bossi, E. The “www” of *Xenopus laevis* Oocytes: The Why, When, What of *Xenopus laevis* Oocytes in Membrane Transporters Research. *Membranes* **2022**, *12*, 927. <https://doi.org/10.3390/membranes12100927>

Academic Editors: Agenor Limon and Cesar Mattei

Received: 23 August 2022

Accepted: 23 September 2022

Published: 25 September 2022

Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Introduction

Fifty years after the first heterologous expression of a protein in *Xenopus laevis*, it is necessary to wonder why it is still used in membrane protein studies, when it is the appropriate model, and, finally, what kinds of experiments are worthwhile to perform with these cells. *Xenopus laevis* oocytes have been used for a long time in the study of membrane proteins, particularly in the functional characterization of transporters and channels, and they are specific model systems. *Xenopus laevis* oocytes are fully equipped with translational machinery [1–3] as the full-grown oocyte is a repository of maternal mRNAs and proteins ready for early embryogenesis; these tools can be exploited to translate and correctly localize exogenous, microinjected RNAs. Consequently, the expression of heterologous proteins is usually very high with a very low background signal. A great number of endogenous electrogenic proteins and membrane conductance are characterized and known [4–14]. The multimeric proteins are correctly assembled (more details are reported in these references [15–18]), and the biophysical parameters are comparable to those collected with different approaches in the primary culture [19], cell line [20,21], and native membrane environment [22]. Moreover, they are giant cells; a mature oocyte has a diameter of about 1–1.2 mm; and they can be easily prepared, injected, and tested with different

approaches. In this review, different examples of applications, tricks, and protocols useful for characterizing membrane protein are reported (Figure 1) with the goal of suggesting new and old methods to solve problems in membrane transporter studies, showing how *Xenopus* oocytes are still a formidable tool for studying a large variety of significant biological questions.




Figure 1. Schematic drawing of use and applications of *Xenopus laevis* oocytes. Each section represents a possible use of *X. laevis* oocytes described in this paper. The use of oocytes as a heterologous expression system allows amplification of the signal and characterization of defined membrane protein(s) starting from cRNA or the original membrane where the protein(s) was previously expressed. Isolated tissue from human or animal models can be microtransplanted in *X. laevis* oocytes studying

a plethora of channels and receptors with native properties maintained in the native environment. Chromatography and spectrofluorimetric procedures can be performed to quantify the presence of substrate inside the *Xenopus laevis* oocytes. Electrogenic membrane proteins can be investigated via TEVC. *X. laevis* oocytes injected with cRNA of interest or transplanted with tissue samples can be also tested for function using radiolabelling or fluorimetric assay and for expression by immunochemistry techniques.

2. *Xenopus laevis* Oocytes as a Heterologous System of Expression

2.1. mRNA Injection

In the early 1970s, Gurdon [23–26] reported the capability of amphibian oocytes to translate foreign mRNA. Ten years later, Sumikawa [27] and Miledi [28–30] expressed and studied functional membrane proteins.

Xenopus laevis oocytes have a highly efficient biosynthetic apparatus that performs all the post-translational modifications needed for correct protein targeting and function; it is possible to co-express different proteins or subunits by co-injections of the corresponding mRNAs [31]. After 48–72 h, if the cRNA is transcribed from a suitable plasmid construct (see the indication in Appendix A), the proteins are translated into exogenous proteins ready to be tested for their functionality. It is necessary to remember that the expression is transient, according to the stability of the mRNA and the half-life of the protein; it lasts for two to seven days. In the culture medium, the selected and the injected oocytes can stay healthy for many days. They can be used with the method described here for about 10 days from the collection day.

2.2. Membrane Microtransplantation from Native Tissues

The possibility of studying the properties of heterologous proteins is not limited to mRNA injection. An effective tool for studying exogenous proteins is also offered by the technique of microtransplantation of receptors and channels from native tissues into *Xenopus laevis* oocytes.

Although the oocyte represents a powerful approach to studying different membrane proteins and their functional and pharmacological properties, it is not able to completely reflect the native environment, which could confer modifications in the functionality of membrane proteins compared to that seen in oocytes. Interestingly, *Xenopus laevis* oocytes can be used to overcome this limitation through the technique of microtransplantation of membrane patches from human (or from other species) tissues [32,33]. This technique allows the study of the original membrane proteins and the associated molecules, as interaction or anchoring proteins are still embedded in their natural lipid environment. Indeed, it is possible to investigate the neurotransmitter receptors and ion channels that maintain all their native properties. Starting from a very small amount of tissue, the great advantage of microtransplantation in *Xenopus laevis* oocytes is that it enables the use of human samples (from autopsies or patients who have undergone surgery) to perform functional studies. This approach has been revealed to be widely useful in many fields, allowing the characterization of the role of membrane proteins in different human diseases, from neurodevelopment disorders to neurodegeneration pathology, epilepsy, and channelopathies [34–39]. Particularly, membranes tissue transplantation allows the investigation of the role of neurotransmitters, such as GABA, glutamate, and acetylcholine, in human brain diseases where impairment of neurotransmitters or their cognate receptors or altered levels of ion concentration can induce brain damage. This technique can also be applied for the screening of novel drug compounds directly on active membrane proteins as hypothetical targets [40,41]. Oocytes microtransplanted with membrane fragments can help us to understand the mechanisms of action of substances (i.e., inflammatory mediators) on the ion channels present in the original tissue [38,42]. Using the transplantation of cortical membranes from Temporal Lobe Epilepsy (TLE) patients in *Xenopus laevis* oocytes, the role of EPO in improving the functionality of the GABAA receptors was demonstrated [43]. GABAergic and glutamate transmissions have been studied in Rett syndrome

through the microtransplantation method, comparing the electrophysiological results obtained from injected tissues from the human and murine cortexes in *Xenopus laevis* oocytes [44]. Via microtransplantation of human muscle membranes, Palma et al. studied functional acetylcholine receptors (AChRs) isolated from muscle biopsies of patients with Amyotrophic Lateral Sclerosis (ALS), assuming that AChR is a useful target for ALS pharmacological therapy [45]. The above examples highlight the ability of oocytes to enable the study of specific human pathologies from small amounts of pathological tissue without any kind of alteration induced by endogenous cell machinery. A single oocyte can integrate the transplanted membrane fragments into its membrane, allowing for the direct study of ion channels or receptors in their native environment (e.g., by TEVC). Details about membrane preparation and microinjection are reported in Appendix A.

3. Testing the Function of Membrane Proteins

Once the proteins are correctly expressed, there are many different approaches to test their functionality. Descriptions of some of the methods are reported in this paragraph with relatively useful literature suggesting when the *Xenopus laevis* oocytes are a perfect tool and what results can be achieved using them by which experimental approach.

3.1. Classical TEVC

The functional study of protein expressed in *Xenopus laevis* oocytes historically uses electrophysiological recording by two-electrodes voltage clamp (TEVC), which is the standard technique due to the dimension of the oocytes. The possibility of controlling the membrane voltage allows the researcher to collect data about the ionic current in defined experimental conditions. Membrane voltage, external solution, substrates, and agonists can be easily applied and modified during the experiments, and it is also possible to inject drugs, chelators, substrates, and ions inside the cell during the experiments. Specifically, a TEVC experiment consists of the recording of the whole oocyte membrane current while applying membrane voltage changes and/or exchanging the extracellular solution through the perfusion system [46,47]. The change in the electrogenic ion fluxes across the membrane is measured as a variation of the current, i.e., equal in amplitude but opposite in sign, at the output of the amplifier connected to the current electrode. By convention, the influx of anions (or efflux of cations) is reported as an upward deflection (outward or positive current) and the influx of cations (efflux of anions) as a downward deflection (inward or negative current). Some proteins drive ions in precise directions (downward with the electrochemical gradients) as many ion channels, but some others can simultaneously transport two or three different types of ions that may have opposite charges or that are translocated in opposite directions [48] (also against their electrochemical gradient); the total ion charge across the membrane is due to a movement of different charges in a different direction.

Xenopus laevis oocytes in the 1990s had a very important role in membrane transporter characterization. After the first solute carriers were cloned [49,50], a great amount of RNA coding for similar proteins became available, and the main tool for their characterization was the expression cloning technique [51], which contributed to the knowledge of the substrates of a huge number of transporter proteins. In this paper [52], it is possible to find an update of the technique with a comprehensible protocol.

Solute carriers are still understudied [53–55], and their roles in physiology, pathology, drug targeting, or drug delivery are continuously growing in importance. Our experience in investigating these proteins is the basis of the experimental suggestion described in this review, with which we would like to help researchers to find the right methods to improve knowledge of SLC proteins.

The possibility of expressing heterologous recombinant cDNA is fundamental not only to understanding the function of the protein but also to identifying the role of the different functional determinants such as single amino acids, the specific transmembrane domain, or internal or extracellular loops. There are hundreds of examples of mutants or

chimeric proteins that anticipated the discovery of the localization or the function of the transmembrane domains or single determinants, confirmed years later by the crystal structure. Kanner [56,57], by cysteine scanning and mutagenesis, identified the possible role of the first transmembrane domain of the SLC6 family established by LeuT_{Aa} structure [58]. Given the possibility of creating recombinant proteins, another interesting approach is the construction of chimera proteins [59–63], for example, to identify the substrate and ions binding site. The same approaches can be also used to express a protein at the plasma membrane even if, *in vivo*, it is expressed in a different compartment; this can help to characterize the transport by TEVC in *Xenopus laevis* oocytes [64,65].

The possibility of changing specific residues can also modify the electrogenicity of the transporter [66] or explain the differences between orthologs; this approach is widely used to recognize the activity of mammalian transporters [67–73].

In the field of membrane transporters research, the possibility of working with mutants, in the beginning, was the basis for understanding the structure and functional relationship between the different domains of the proteins. After the crystal structures, single and multiple mutants became the tools for confirming the functional role of the regions identified by the solved structure [71,74–82].

Introducing one or multiple amino acid substitutions in membrane transporters is quite simple because it is possible to easily modify the cDNA sequences of the original transporters using an appropriate commercial kit or available protocols [83–85]. Once the cDNA has the desired mutations, it can be easily transcribed, and the corresponding cRNA and the mutated protein are produced by the oocytes. The importance of this approach is certified by thousands of publications. In many cases, the current elicited by the electrogenic transporter is large enough that possible reduction of the function of the mutated transporter can be still characterized as the currents are still easily measurable.

Again, due to the size of the currents, it is also possible to appreciate changes in their shape; this is particularly true if pre-steady-state currents are investigated. These currents are slow, transient currents related to the presence of the transporter in the plasma membrane and are only observed in oocytes expressing membrane transporters that present electrogenic steps in their transport cycle (Figure 2). These currents are elicited by voltage jumps or concentration jumps applied to oocytes expressing the transporter of interest [86–89]. The recorded currents are visible in the absence (in the majority of the cases) or even in the presence of the substrate (in many cases for concentrations below the saturating concentration of the substrate [77,90,91]). The pre-steady-state currents are a tool for studying the interaction between ion(s) and substrates and the transport protein during the translocation cycle. Moreover, in some cases, they are also helpful for verifying the localization of specific residues (i.e., charged residues) in the membrane electric field [92–96] or to determine the apparent affinity of the transporter for a specific substrate [77].




Figure 2 The cartoon modified from [87] represents a simple scheme of two of the many other states from the transport cycle: the outward open conformation ready to bind the substrate (left) with the substrates bound (center) and the inward open conformation with the released substrate. The pre-steady-state currents are visible when a rapid voltage change is applied. The ions are moved deeper into the transporter vestibule, or (and) charged residue(s) are rearranged. The charges moved in the membrane electric field change the amount of charge of the membrane capacitor and can be revealed as a slow relaxation of the oocyte capacitive current. These currents are isolated from the endogenous capacitive currents by the subtraction of the current recorded in the presence of an inhibitor (when available) or by a double exponential fitting [97], considering the fast component related to the capacitor behavior of the plasma membrane of the oocytes and the slow behavior to the presence in the membrane of the transporter. The pre-steady-state currents are transient; the area under the transient at the “on” of the voltage pulse is equal to that of the “off” and shows saturation at extreme positive and negative voltages [93]. In the absence of a substrate, the charges cannot move further, so, when the voltage comes back to the starting value, the charges move out, giving rise to the transient off. The integration of the area of the relaxation allows quantification of the number of the charges involved. When the substrate is present, it elicits conformational changes, completing the transport cycle to the inward open conformation (right) moving substrate and co-transporter ions inside the cell, generating the transport current. The inward open conformation is simply schematized by the opening of the gate in the presence of the substrates. On the right is an example of transient currents and transport currents and the data that can be collected from them regarding the Q/V (charge/voltage) and I/V (current/voltage) relationship.

For some transporters, the pre-steady-state currents are particularly large and represent a means for specific biophysical characterization, for example, GAT1 (slc6a1) [86,98], SGLUT (SLC2) [99], PepT1 and 2 (SLC15) [91,94,96,100], and NaPi (SLC34) [101]. Another interesting aspect of the heterologous expression of membrane transporter in *Xenopus laevis* oocytes is the possibility of testing the behavior of the same cell at different temperatures to estimate the steps of the transport cycle that require larger conformational changes. The larger variation of the temperature coefficients (Q_{10}) for the different parameters that can be acquired is related to larger conformational changes involved in that specific function; the weaker temperature sensitivity is, instead, related to the diffusional component of the process [92,95,102–104].

Xenopus laevis oocytes have the capability of correctly expressing the different subunits that can be exploited to understand the role of every single subunit in the ion channels, but, also in membrane transporter research, the role of subunits can be investigated [105], even with a peculiar construct [106].

Xenopus laevis oocytes are also used to study reverse transport, i.e., by injecting the substrates. This approach can be particularly helpful for understanding the interaction with the different ions in the transport cycles [107,108]. Moreover, due to the dimension of the cells, it is also possible to evaluate the changes in the intracellular contents, i.e., pH changes [109]. The intracellular environment can be also changed by co-expressing ion exchangers or with specific incubation solutions [110]. The concentration of Cl^- can be estimated [108] using the presence of endogenous CaCC (Ca^{2+} -gated Cl^- channel) [5]. This channel, constitutively present in mature oocytes, is one of the most widely used tools in the investigation of exogenous metabotropic receptors in *Xenopus laevis* oocytes. Since 1987, when the acetylcholine- and neurotensin-evoked responses of oocytes were studied, the activation of this channel by the DAG/IP3 signaling pathway has been used to characterize an impressive number of G-protein-coupled receptors that have been exhaustively characterized in the oocyte [111–113]. Similarly, *Xenopus laevis* oocytes are useful tools for studying “Store-Operated Ca^{2+} Entry” (SOCE). In the paper of Courjaret [114], different methodologies to investigate this pathway are reported.

3.2. Voltage Clamp Fluorimetry (VCF)

Xenopus laevis oocytes can be utilized to investigate the conformational movements of single amino acid residues by monitoring the changes in fluorescence emitted by a fluorophore attached to the residues in the selected positions. With high temporal resolution, this functional investigation provides information on the conformational changes in a protein when its environment is changed in terms of substrates, voltages, pHs, etc., simultaneously allowing observation of its function (Figure 3). The power of functional, site-directed fluorometry is elegantly reported in [115]. The technique is applied to study the interactions of the electrogenic protein with modulators. An example of applications of VCF to membrane transporters is reported by Virkki et al. [116]; this paper details the set-up used. Oocytes and VCF have been also used to improve optical voltage indicators [117].




Figure 3. Identified residue is mutated in cysteine that can be bound to a fluorophore. The engineered cysteine residue with the tethered fluorophore is represented by the green star. Changes in

membrane potential, pH, and concentration cause fluorophore displacement, changing the fluorophore environment and, consequently, fluorescence emission. Membrane current and fluorescence intensity can be simultaneously measured. A detailed explanation of the methods can be found here: [118,119].

4. Testing the Expression of Membrane Proteins

4.1. SOC and Immunochemistry

When mutants are expressed in *Xenopus laevis* oocytes and show loss or gain of function, revealed by the previously described technique, it is necessary to verify the possible alteration of the expression of the transporter at the level of the plasma membrane. The quantification of the protein can also be useful for investigating the effect of modulation or the co-expression of accessory subunits. The immunostaining of heterologous protein is a valid tool not only for detecting and quantifying the expression, but also for following the trafficking of the protein [120,121] or verifying the targeting on the plasma membrane [122], even if the correct targeting is, in many cases, verified by the function; when the function is hampered, confirmation of the presence or the absence of the protein at the plasma membrane becomes of great importance [123]. It is also useful to point out that the classical Western blot technique is not the first choice for investigating the presence of the heterologous protein at the plasma membrane, primarily because the high presence of lipoprotein in many cases masks the signals and because it requires the separation of the membranes [124] and/or the application of immunoprecipitation techniques [18,125], or the biotinylation of the membrane protein [72,106]. Western blot from homogenized oocytes requires specific tricks to even verify the presence of cytosolic proteins [123,126]. To our knowledge, there are two other effective immunochemistry techniques for investigating exogenous proteins in *Xenopus laevis* oocytes which are easier and less time-consuming, even if they are not applicable for all the proteins expressed.

One of these approaches is Single-Oocyte Chemiluminescence (SOC), which allows a comparison of the amount of protein expressed on the oocyte membrane in different groups of differently treated oocytes or expressing mutants or accessory subunits. Zerangue et al. [127] are the pioneers of this approach. The SOC technique uses classical immunostaining on the whole oocyte labeled with a secondary antibody conjugated to Horseradish Peroxidase (HPR). Many oocytes can be tested at the same time, and the chemiluminescence can be detected in a 96-well plate using a luminometer. The oocytes are fixed in paraformaldehyde and incubated in the primary and in the secondary antibody peroxidase conjugate, allowing signal detection proportional to the amount of protein present in a single oocyte (see Appendix A for detailed protocol). The chemiluminescence emitted is quantified with a microplate reader. An advantage of this technique is that the detection on a multiwell plate and data collection from a single oocyte allows the analysis of many cells at the same time, providing statistically significant numbers in a shorter time than other techniques. SOC is a valid approach for comparing the amount of mutant protein expressed at the plasma membrane and verifying the relationship between the function and the amount of protein present in the plasma membrane. One example of this approach was the correlation between the function and the expression of some rbPepT1 mutants demonstrated by Bossi et al. This paper [122] reported the electrophysiological characterization of FLAG-rbPepT1 mutations in charged residues, with the example of non-functional mutants that, in one case, were correctly localized in the membrane, but, in another, the introduced mutations completely impaired the correct localization of the membrane. In this case, a modified protein with a FLAG sequence in the V extracellular loop was used [128]. The quantification of the expression by oocytes can also be used to evaluate the effect of the presence of the accessory protein, as reported for B0AT1 [105]. In our experience, this technique works when the antibody is against a sequence located in the loops spanning the extracellular side of the protein, possibly in extracellular loops. Epitopes located in the transmembrane domains or the intracellular

loops are not (well) recognized. Moreover, cytoplasmatic proteins cannot be labeled because of the presence of the membrane that, even if partially permeabilized, limits the diffusion of the antibody inside the cell due to the dimension. The localization of the heterologous protein can also be performed by the immunostaining of the oocytes' section. With this technique, cytoplasmatic proteins or internal epitopes can be well recognized. Oocytes, in this case, are fixed with 4% paraformaldehyde embedded into a cryo-embedding compound (Polyfreeze tissue-freezing medium), frozen in liquid nitrogen, and cut into thin (7 μm) sections with a cryostat. Then, the slices are incubated with the primary and secondary antibody fluorophore conjugate and visualized by a fluorescence microscope, as detailed in Appendix A.

5. Alternative Methods to Quantify the Functionality

There are experimental conditions where it is not possible to investigate the function of the protein expressed by applying classical approaches. In our research experience, we have developed, modified, or identified specific strategies to overcome the various obstacles that arise in peculiar investigations. To increase the power of *Xenopus laevis* oocytes as a research tool, we report some suggestions to better utilize this system.

5.1. Fluorescence Monitoring

Autofluorescent and opaque oocytes have been used on several occasions to monitor fluorescent molecules, both as substrates and as indicators [129–131] (Figure 4). The paper of Illing [130] is a milestone in using fluorescence for monitoring the functionality of membrane transporters. It provided validation for the use of PhenGreenSK fluorescence quenching as a marker of cellular metal ion uptake. In this paper, they determined the metal-ion selectivity of DMT1 (SLC11a2) in specific conditions using a voltage clamp, radiotracer, and fluorescence assays, validating the methods. For the characterization of the dictyostelium discoideum orthologs of DMT1, NRAMP1, and 2, calcein, a more common (and cheaper) fluorescence indicator, was used both in the cells of the amoeba and in *Xenopus laevis* oocytes [64]. In this work, the quenching of calcein was monitored by confocal microscopy on a single oocyte, but the technique also works with basic LED-based fluorescence microscopy with equal detection capacity, as reported in [132] and as shown in the various experiments carried out to validate the method and in the subsequent peculiar oocytes applications [133,134]. The method proposed by Illing and modified by our group works well, but it has two disadvantages. First, it requires a lot of time to test the number of samples to achieve statistical significance, considering that, according to the transporter efficiency/activity testing, the quenching of one oocyte requires between 5 and 30 min. The second problem is related to the autofluorescence of the oocytes, which changes from batch to batch, and, consequently, needs collecting for each experiment, as well as several reference samples. To solve the first problem, Cinquetti et al. [135] developed a method in which the quenching of the fluorophore was used to indirectly monitor the translocation of substrates or ions, using a plate reader to collect a satisfactory number of data at the same time. The technique reported in [135] can be applied to measure the difference of the fluorescence in a cytoplasmic extract from the oocytes exposed or not to the substrate and is able to quench the fluorophore, indirectly measuring the uptake. In the same paper, autofluorescence was also investigated in this kind of assay.




Figure 4. A fluorophore that reduces or increases its emission in the presence of the substrate can be used to monitor the changes inside the oocytes. Calcein reduces its emission intensity when interacting at physiological pH with divalent cations. Calcein-injected oocytes expressing the divalent metal transporter DMT1 (slc11a2) are incubated in a solution containing Me^{2+} . It is possible to follow the fluorescence quenching by monitoring the decay of fluorescence intensity with a fluorescence microscope. It is also possible to measure the final fluorescence intensity in many oocytes at the same time, incubating them in solution with or without the Me^{2+} , and measuring the fluorescence intensity of the supernatant obtained after the homogenization and centrifugation of the oocytes.

Detailed protocols for the use of fluorescence indicators to monitor the changes in the content of the cytoplasmic environment, and, consequently, indirectly the oocytes uptake, can be found in the cited papers, and a good strategy to avoid the problem with autofluorescence is reported in [136].

5.2. Monitoring the Transport by HPLC, GC-MS

One of the classic methods of screening and profiling compounds for a transporter is the radiolabeled cellular uptake [52]. This method provides solid evidence of the substrate or inhibitor characteristics of a compound, but it also produces unwanted radioactive waste while involving a time-consuming, costly procedure to radiolabel the compounds. Moreover, in recent years, many institutions have preferred radioactive-free experiments because working with radiolabeled compounds, when they exist, has high costs, high risks for the staff and the environment, and requires a specifically controlled and isolated working area. As an economical, accurate, and time-efficient method, high-performance liquid chromatography (HPLC) provides a very appealing alternative but is still underused. Since the 1950s, scientists have been optimizing different protocols for chromatographic separation using HPLC, but preparing the sample and choosing the right detector for analyzing the cytoplasmic content of the oocytes remains a challenge. Consequently, only a small number of papers have reported HPLC as a method for quantifying uptake in *Xenopus laevis* oocytes, even if it has been used since the 1990s [137].

The HPLC-based approach for *Xenopus laevis* oocytes expressing transporter provides a time- and cost-efficient tool for profiling known and unknown compounds [138]. This method, when combined with TEVC, can provide a correlation between the substrate

and the charge translocation and allow discriminate between the real substrate and possible molecules acting as channel openers, as reported in [139]; in this paper, the D-serine was confirmed to be a substrate of KAAT1 (K⁺-coupled amino acid transporter 1).

5.3. High-Throughput Systems

Conventional electrophysiological experiments using a manual, two-electrode voltage clamp provide robust, high-resolution, and direct results for electrogenic protein activities but a low turnover. Given the sheer number of compounds to be tested and the unclassified transporters, ion channels, and receptors, it is essential to develop sensitive, automated, and optimized processes for direct electrophysiological measurements [140]. Several groups have developed high-throughput systems with automated recording stations for TEVCs. The Roboocyte™ (developed by MCS GmbH, 72770 Reutlingen - Germany) allows automated cDNA/cRNA microinjection into *Xenopus laevis* oocytes and TEVC recording from oocytes in a 96-well plate. Another system, named OpusXpress™ (developed by Axon Instruments, USA), can run experiments using eight recording stations. The Parallel Oocyte Electrophysiology Test stations (POETs™ developed by Abbot Laboratories, Abbot Park, USA) provide a throughput of ~14 plates/day (96-well) and are extensively used to study ligand-gated ion channels [141,142]. As technology grows, these companies also upgrade their high-throughput systems. For example, the Roboocyte™ was upgraded and launched as Roboocyte2™ with upgraded acquisition software, faster solution exchange, and a compact design with increased automation.

As a general concept, these automated devices can measure 96 oocytes in one go, using the standard, commercially available 96-well plates. The perfusion systems are controlled by a robot head, but scientists can also modify the system as needed. These systems have been used to study GABA receptors, Na⁺/K⁺-ATPase transporter, and various ion channels [140,142,143]. These automated high-throughput systems have had an impact, increasing the contribution of electrophysiology (using oocytes) for studying the effects of substrate compounds and discovering new molecules.

6. Conclusions

The techniques reported here are only a partial summary of the possible applications available that use *Xenopus laevis* oocytes in research. The methodologies examined are mainly related to research in the field of membrane transporters, which is our research activity. This work is certainly not exhaustive, but we hope it will be useful to researchers who want to quickly find suggestions and detailed indications when investigating the functionality and expression of the different members of the solute carrier families.

Author Contributions: Conceptualization, E.B.; methodology, R.C., C.R., M.B., A.D.I. and T.R.; investigation, E.B., R.C., C.R., M.B., A.D.I. and T.R.; writing—original draft preparation, E.B., M.B., A.D.I. and T.R.; writing—review and editing, E.B., C.R. and M.B.; supervision, E.B.; funding acquisition, E.B. All authors have read and agreed to the published version of the manuscript.

Funding: This project received funding from the European Union's Horizon 2020 research and innovation program under Marie Skłodowska-Curie grant agreement no.860954.

Institutional Review Board Statement:

The research involving *Xenopus laevis* oocytes was conducted using an experimental protocol approved locally by the Committee of the “Organismo Preposto al Benessere degli Animali” of the University of Insubria and by the Italian Ministry of Health (n.449/2021-PR).

Data Availability Statement:

This review do not report no unpublished data-

Conflicts of Interest: The authors declare no conflict of interest.

Appendix A

Protocols and experimental details.

Appendix A.1. Oocytes Collection Procedure

- Anesthetize the frog by immersion in 500 mL of tricaine methane sulfonate, check the pH, and, in case, adjust with bicarbonate solution (750 mg⁻¹g) to pH 8.
- Sterilize the frog's abdomen with an antiseptic agent (povidone iodine, 0.8%);
- Uplift the skin in the lower abdominal quadrant and make a 10 mm incision using a pair of sterilized, small scissors. This exposes the body wall, which is then cut (0.5 cm) using the same technique.
- Remove the portion of the ovary and collect the oocytes in a tube containing ND96 Ø Ca²⁺;
- Suture both the incisions in the body wall muscle and the skin using stitches of absorbable synthetic thread.
- Leave the frog for one/two hours post-surgery in a small tank with 3 liters of FETAX solution until complete recovery from anesthesia.

Appendix A.2. Oocytes Preparation Procedure

- Using sterilized tweezers, split the ovary into small pieces: groups of 8–10 oocytes in a Petri dish containing ND96 Ø Ca²⁺.
- Wash the cluster of oocytes twice in clean ND96 Ø Ca²⁺ and move the oocytes into a 15 mL tube containing 5 mL of collagenase solution.
- Treat the oocyte groups in the collagenase solution with continuous agitation for about an hour at 18 °C to separate the single oocytes and remove the follicular membrane.
- Wash the oocytes three times with ND96 Ø Ca²⁺ and three times with NDE solutions.
- Transfer oocytes to a 90 mm Petri dish containing NDE medium solution and incubate for at least 90 min at 18 °C;
- Select the healthy and fully grown oocytes (stage V and VI) under a stereomicroscope and transfer them to a fresh Petri dish containing NDE medium.

Appendix A.3. Selection Criteria

- Well-composed and spherical;
- The distinct partition between animal and vegetal poles;
- Homogenous pigmentation in animal and vegetal poles;
- Absence of follicular membrane.

Appendix A.4. Membrane Tissue Extraction Procedure

- Homogenize the frozen tissue sample (about 0.5 g) using a Teflon glass homogenizer in 2 mL of glycine buffer at pH 9 (200 mM glycine/150 mM NaCl/50 mM EGTA/50 mM EDTA/300 mM sucrose), adding 20 µL of protease inhibitors (Sigma 2714, St. Louis, MO, USA);
- Centrifuge for 15 min at 9500× g at 4 °C (Beckmann centrifuge, C1015 rotor);
- Centrifuge the obtained supernatant for 2 h at 100,000× g at 4 °C (Beckmann centrifuge, SW40 rotor).
- Wash the final pellet with H₂O and resuspend it in 5 mM glycine.
- Store the aliquots at −80 °C or use them directly.
- Inject the membrane samples (50–100 nL/ 0.2–10 mg protein/mL) into oocytes using a manual microinjection system (Drummond Scientific Company, Broomall, PA, USA).

Appendix A.6. Expression Vector

To generate cRNA from DNA encoded with the protein of interest, it is subcloned into a plasmid vector with specific characteristics suitable for expression in *Xenopus laevis* oocytes.

The essential features of this plasmid are:

- The presence of a promoter site for RNA polymerase (T7 or SP6) upstream of the open reading frame (ORF). It is better to use a T7 or SP6 promoter since the T3 polymerase has generally been shown to give rise to an unstable transcript (in our experience, T7 always works better).
- A polyA tail is needed to stabilize the construct.
- A multiple cloning site allows subcloning of the transporter cDNA downstream of the promoter and upstream of the polyA tail.
- It is also important that the untranslated region between the RNA polymerase promoter (T7, T3, or SP6) is as short as possible or has the presence of 5' and 3' untranslated regions derived from the *Xenopus laevis* protein, usually the β -globin, which is efficiently translated in microinjected oocytes.
- The sequences flanking the initiation codon within the cDNA can be modified by site-directed mutagenesis so that they conform to the optimal translation initiation sequence, GCCGCCA/GCCmG. The presence of both a purine at position -3 and a G at the position at +4 is sufficient to direct optimal translation.
- A unique restriction site downstream of the transporter ORF that allows linearization of the transporter. Restriction enzymes that generate blunt ends or 5' overhangs are preferred.

Some examples of the useful vector are: pGEMHE [144], pGH19 [145], pAMV [146], pOO2 [147], and pGem-He-Juel [148]

Appendix A.7. RNA Preparation Procedure

- Transform the recombinant plasmids expressing the gene of interest into the JM109 strain of *E. Coli* by performing a heat-shock procedure and letting the colony grow at 37 °C overnight.
- Inoculate a single colony in a liquid selective medium specific for plasmid resistance and incubate at 37 °C overnight under constant agitation.
- Extract the plasmid DNAs using Wizard® Plus SV Miniprep (Promega Italia, Milan, Italy).
- To achieve an efficient in vitro transcription, linearize the recombinant plasmid with a restriction enzyme which generates blunt ends or 5' overhangs.
- Purify with Wizard SV Gel and PCR clean-up system (Promega Italia).
- Compose the in vitro transcription reaction as follow: 18 μ L of transcription buffer 5X, 8 μ L of DTT 100 mmol/L, 2 μ L of RNasin® ribonuclease inhibitors 40 U/ μ L, 13 μ L rNTPs mix (rATP, rCTP, rUTP 5 mmol/L and rGTP 0.5 mmol/L), 6.5 μ L of cap analog 10 mmol/L, 10 μ L T7 RNA polymerase 20 U/ μ L (final volume 90 μ L). After 10, 20, and 40 min from the beginning of the incubation, add 1 μ L of rGTP 25 mmol/L. After 1 h from the start of the transcription, add a mix of 4 μ L of transcription buffer 5X, 1 μ L of DTT 100 mmol/L, 1 μ L of RNasin® ribonuclease inhibitors 40 U/ μ L, 5 μ L of rNTPs mix, 1 μ L of T7 RNA polymerase 20 U/ μ L, 1 μ L of GTP 25 mmol/L, 4 μ L of nuclease-free water. Wait 2 h. Add 101 μ L of nuclease-free and 150 μ L of LiCl 8 mol/L and store at -80 °C overnight. The next day, precipitate and wash the transcribed cRNA with EtOH 70% to obtain the purified cRNA.
- Quantify the cRNA by NanoDrop™ 2000 Spectrophotometer (Thermo Fisher Scientific, Waltham, MA, USA).
- Store the samples at -80 °C.
- Inject 50 nL of the cRNA (for the solute carrier, the concentration is always between 0.25 and 0.5 μ g/ μ) in each oocyte using a manual microinjection system (Drummond Scientific Company, Broomall, PA, USA).

Appendix A.8. SOC (Single-Oocyte Chemiluminescence)

- Transfer oocytes (5–10 in each well) into a 24-well plate with 500 μ L of ND96;
- Wash using 500 μ L ND96 cold in mild agitation (5 min at RT, three times);

- Fix with 500 µL of 4% paraformaldehyde in ND96 and shake the multiwell at 4 °C for 15 min;
- Wash using 500 µL ND96 cold in mild agitation (5 min at RT, three times);
- Block with 500 µL blocking solution and shake at 4 °C for 1 h.
- Incubate oocytes with 300–600 µL of AB I°, diluted, according to the kind of AB at defined concentration, in blocking solution and shake at 4 °C for 1 h.
- Wash using 500 µL blocking solution in mild agitation (5 min at 4 °C, three times).
- Incubate oocytes with 300–600 µL of AB II° conjugated to Horseradish Peroxidase (HPR) diluted, according to the manufacturing indication, in blocking solution and shake at 4 °C for 1 h.
- Wash using 500 µL blocking solution in mild agitation (5 min at 4 °C, three times).
- Wash the oocytes for the last time with ND96 in mild agitation at RT for 10 min.
- In a 96-well costar white flat bottom plate, put 50 µL of SuperSignal (Thermofisher); Transfer the oocytes to the wells with LUMINOL and incubate for 1 h before reading the luminescence in the plate reader.

Appendix A.9. Immunohistochemistry

- Transfer oocytes (5–10 in each well) into a 24-well plate with 500 µL of ND96.
- Wash using 500 µL ND96 cold in mild agitation (5 min at RT, three times);
- Fix with 500 µL of 4% paraformaldehyde in ND96 and shake the multiwell at 4 °C for 15 min.
- Wash using 500 µL ND96 cold in mild agitation (5 min at RT, three times).
- Include the oocyte in Polyfreeze tissue-freezing medium and then freeze in liquid nitrogen.
- Use a cryostat to obtain oocyte cryosections (7 µm thickness) and store at −20 °C until immunostaining.

Appendix A.10. Solutions

- Anesthetic solution: Dissolve 500 mg tricaine (ethyl 3 aminobenzoate methane sulfonate) in 500 mL MilliQ water. Add sodium bicarbonate (750 mg·g^{−1}) to the anesthetic solution until pH > 8;
- FETAX: NaCl 10.69, NaHCO₃ 1.14, KCl 0.4, CaCl₂ 0.1, CaSO₄ 0.35, MgSO₄ 0.62 (in mM);
- Collagenase solution: dissolve collagenase from *Clostridium histolyticum* (collagenase type IA from *Clostridium histolyticum*, C0130 from Sigma-Aldrich) in ND96 Ø Ca²⁺. Use a concentration of 1–2 mg/mL according to the FALGPA value stated in the production batch specifications.
- ND96Ø: NaCl 96, KCl 2, MgCl₂ 1, and HEPES 5 (in mM), to pH 7.6 with NaOH.
- ND96: NaCl 96, KCl 2, CaCl₂ 1.8, MgCl₂ 1, and HEPES 5 (in mM) to pH 7.6 with NaOH.
- NDE: ND96 with pyruvate 2.5 mM, and 50 µg/mL gentamycin sulphate.
- Blocking solution: 50 mL ND96 + 0.5 g BSA.

References

1. Dascal, N.; Lotan, I. Expression of exogenous ion channel and neurotransmitter receptor in RNA-injected *Xenopus* oocytes. In *Methods in Molecular Biology, Vol 13: Protocols in Molecular Neurobiology*; Bausch, S., Prevest, A., Eds.; The Humana Press: Totowa NJ, USA, 1992; Volume 13, pp. 205–225.
2. Richter, J.D.; Smith, L.D. Differential capacity for translation and lack of competition between mRNAs that segregate to free and membrane-bound polysomes. *Cell* **1981**, *27*, 183–191. [https://doi.org/10.1016/0092-8674\(81\)90372-x](https://doi.org/10.1016/0092-8674(81)90372-x).
3. Meric, F.; Searfoss, A.M.; Wormington, M.; Wolffe, A.P. Masking and unmasking maternal mRNA: The role of polyadenylation, transcription, splicing, and nuclear history. *J. Biol. Chem.* **1996**, *271*, 30804–30810. <https://doi.org/10.1074/jbc.271.48.30804>.
4. Kusano, K.; Miledi, R.; Stinnakre, J. Cholinergic and catecholaminergic receptors in the *Xenopus* oocyte membrane. *J. Physiol.* **1982**, *328*, 143–170.
5. Terhag, J.; Cavara, N.A.; Hollmann, M. Cave Canalem: How endogenous ion channels may interfere with heterologous expression in *Xenopus* oocytes. *Methods* **2010**, *51*, 66–74. <https://doi.org/10.1016/j.jymeth.2010.01.034>.

6. Sobczak, K.; Bangel-Ruland, N.; Leier, G.; Weber, W.M. Endogenous transport systems in the *Xenopus laevis* oocyte plasma membrane. *Methods* **2010**, *51*, 183–189.
7. Tosco, M.; Faelli, A.; Gastaldi, G.; Paulmichl, M.; Orsenigo, M.N. Endogenous lactate transport in *Xenopus laevis* oocyte: Dependence on cytoskeleton and regulation by protein kinases. *J. Comp. Physiol. B* **2008**, *178*, 457–463.
8. Tzounopoulos, T.; Maylie, J.; Adelman, J.P. Induction of endogenous channels by high levels of heterologous membrane proteins in *Xenopus* oocytes. *Biophys. J.* **1995**, *69*, 904–908. [https://doi.org/10.1016/S0006-3495\(95\)79964-7](https://doi.org/10.1016/S0006-3495(95)79964-7).
9. Van Winkle, L.J. Endogenous amino acid transport systems and expression of mammalian amino acid transport proteins in *Xenopus* oocytes. *Biochim. Biophys. Acta* **1993**, *1154*, 157–172.
10. Krafte, D.S.; Volberg, W.A. Properties of endogenous voltage-dependent sodium currents in *Xenopus laevis* oocytes. *J. Neurosci. Methods* **1992**, *43*, 189–193.
11. Bossi, E.; Centinaio, E.; Moriondo, A.; Peres, A. Ca^{2+} -dependence of the depolarization-inducible Na^{+} current of *Xenopus* oocytes. *J. Cell Physiol.* **1998**, *174*, 154–159.
12. Centinaio, E.; Bossi, E.; Peres, A. Properties of the Ca^{2+} -activated Cl^{-} current of *Xenopus* oocytes. *Cell Mol. Life Sci.* **1997**, *53*, 604–610.
13. Weber, W.M. Endogenous ion channels in oocytes of *xenopus laevis*: Recent developments. *J. Membr. Biol.* **1999**, *170*, 1–12. <https://doi.org/10.1007/s002329900532>.
14. Kobayashi, T.; Ikeda, K.; Kumanishi, T. Functional characterization of an endogenous *Xenopus* oocyte adenosine receptor. *Br. J. Pharmacol.* **2002**, *135*, 313–322. <https://doi.org/10.1038/sj.bjp.0704475>.
15. Chen, M.L.; Hoshi, T.; Wu, C.F. Heteromultimeric Interaction among K^{+} Channel Subunits from Shaker and eag Families in *Xenopus* Oocytes. *Neuron* **1996**, *17*, 535–542.
16. Wongsamitkul, N.; Nache, V.; Eick, T.; Hummert, S.; Schulz, E.; Schmauder, R.; Schirmeyer, J.; Zimmer, T.; Benndorf, K. Quantifying the cooperative subunit action in a multimeric membrane receptor. *Sci. Rep.* **2016**, *6*, 20974. <https://doi.org/10.1038/srep20974>.
17. Isacoff, E.Y.; Jan, Y.N.; Jan, L.Y. Evidence for the formation of heteromultimeric potassium channels in *Xenopus* oocytes. *Nature* **1990**, *345*, 530–534. <https://doi.org/10.1038/345530a0>.
18. Shistik, E.; Ivanina, T.; Puri, T.; Hosey, M.; Dascal, N. Ca^{2+} current enhancement by $\alpha 2/\delta$ and β subunits in *Xenopus* oocytes: Contribution of changes in channel gating and $\alpha 1$ protein level. *J. Physiol.* **1995**, *489* (Pt 1), 55–62.
19. Bröer, S.; Rahman, B.; Pellegrini, G.; Pellerin, L.; Martin, J.-L.; Verleystonk, S.; Hamprecht, B.; Magistretti, P.J. Comparison of Lactate Transport in Astroglial Cells and Monocarboxylate Transporter 1 (MCT 1) Expressing *Xenopus laevis* Oocytes: EXPRESSION OF TWO DIFFERENT MONOCARBOXYLATE TRANSPORTERS IN ASTROGLIAL CELLS AND NEURONS*. *J. Biol. Chem.* **1997**, *272*, 30096–30102. <https://doi.org/10.1074/jbc.272.48.30096>.
20. Niu, L.; Vazquez, R.W.; Nagel, G.; Friedrich, T.; Bamberg, E.; Oswald, R.E.; Hess, G.P. Rapid chemical kinetic techniques for investigations of neurotransmitter receptors expressed in *Xenopus* oocytes. *Proc. Natl. Acad. Sci. USA* **1996**, *93*, 12964–12968. <https://doi.org/10.1073/pnas.93.23.12964>.
21. Yang, J.; Cheng, Q.; Takahashi, A.; Goubaeva, F. Kinetic properties of GABA $\rho 1$ homomeric receptors expressed in HEK293 cells. *Biophys. J.* **2006**, *91*, 2155–2162. <https://doi.org/10.1529/biophysj.106.085431>.
22. Keller, K.; Strube, M.; Mueckler, M. Functional expression of the human HepG2 and rat adipocyte glucose transporters in *Xenopus* oocytes. Comparison of kinetic parameters. *J. Biol. Chem.* **1989**, *264*, 18884–18889.
23. Gurdon, J.B.; Lingrel, J.B.; Marbaix, G. Message stability in injected frog oocytes: Long life of mammalian α and β globin messages. *J. Mol. Biol.* **1973**, *80*, 539–551. [https://doi.org/10.1016/0022-2836\(73\)90421-x](https://doi.org/10.1016/0022-2836(73)90421-x).
24. Gurdon, J.B.; Lane, C.D.; Woodland, H.R.; Marbaix, G. Use of frog eggs and oocytes for the study of messenger RNA and its translation in living cells. *Nature* **1971**, *233*, 177–182. <https://doi.org/10.1038/233177a0>.
25. Gurdon, J.B. The translation of messenger RNA injected in living oocytes of *Xenopus laevis*. *Acta Endocrinol. Suppl.* **1973**, *180*, 225–243. <https://doi.org/10.1530/acta.0.074s225>.
26. Lane, C.D.; Marbaix, G.; Gurdon, J.B. Rabbit haemoglobin synthesis in frog cells: The translation of reticulocyte 9 s RNA in frog oocytes. *J. Mol. Biol.* **1971**, *61*, 73–91. [https://doi.org/10.1016/0022-2836\(71\)90207-5](https://doi.org/10.1016/0022-2836(71)90207-5).
27. Sumikawa, K.; Houghton, M.; Emtage, J.S.; Richards, B.M.; Barnard, E.A. Active multi-subunit ACh receptor assembled by translation of heterologous mRNA in *Xenopus* oocytes. *Nature* **1981**, *292*, 862–864. <https://doi.org/10.1038/292862a0>.
28. Miledi, R.; Parker, I.; Sumikawa, K. Properties of acetylcholine receptors translated by cat muscle mRNA in *Xenopus* oocytes. *Embo J.* **1982**, *1*, 1307–1312. <https://doi.org/10.1002/j.1460-2075.1982.tb01315.x>.
29. Barnard, E.A.; Miledi, R.; Sumikawa, K. Translation of exogenous messenger RNA coding for nicotinic acetylcholine receptors produces functional receptors in *Xenopus* oocytes. *Proc. R Soc. Lond. B. Biol. Sci.* **1982**, *215*, 241–246. <https://doi.org/10.1098/rspb.1982.0040>.
30. Miledi, R.; Parker, I.; Sumikawa, K. Synthesis of chick brain GABA receptors by frog oocytes. *Proc. R Soc. Lond. B. Biol. Sci.* **1982**, *216*, 509–515. <https://doi.org/10.1098/rspb.1982.0089>.
31. Nargeot, J.; Dascal, N.; Lester, H.A. Heterologous expression of calcium channels. *J. Membr. Biol.* **1992**, *126*, 97–108. <https://doi.org/10.1007/bf00231908>.

32. Miledi, R.; Eusebi, F.; Martinez-Torres, A.; Palma, E.; Trettel, F. Expression of functional neurotransmitter receptors in *Xenopus* oocytes after injection of human brain membranes. *Proc. Natl. Acad. Sci. USA* **2002**, *99*, 13238–13242.
33. Eusebi, F.; Palma, E.; Amici, M.; Miledi, R. Microtransplantation of ligand-gated receptor-channels from fresh or frozen nervous tissue into *Xenopus* oocytes: A potent tool for expanding functional information. *Prog. Neurobiol.* **2009**, *88*, 32–40.
34. Miledi, R.; Palma, E.; Eusebi, F. Microtransplantation of neurotransmitter receptors from cells to *Xenopus* oocyte membranes: New procedure for ion channel studies. *Methods Mol. Biol.* **2006**, *322*, 347–355. https://doi.org/10.1007/978-1-59745-000-3_24.
35. Palma, E.; Trettel, F.; Fucile, S.; Renzi, M.; Miledi, R.; Eusebi, F. Microtransplantation of membranes from cultured cells to *Xenopus* oocytes: A method to study neurotransmitter receptors embedded in native lipids. *Proc. Natl. Acad. Sci. USA* **2003**, *100*, 2896–2900. <https://doi.org/10.1073/pnas.0438006100>.
36. Mazzo, F.; Zwart, R.; Serratto, G.M.; Gardinier, K.M.; Porter, W.; Reel, J.; Maraula, G.; Sher, E. Reconstitution of synaptic Ion channels from rodent and human brain in *Xenopus* oocytes: A biochemical and electrophysiological characterization. *J. Neurochem.* **2016**, *138*, 384–396. <https://doi.org/10.1111/jnc.13675>.
37. Ruffolo, G.; Cifelli, P.; Roseti, C.; Thom, M.; van Vliet, E.A.; Limatola, C.; Aronica, E.; Palma, E. A novel GABAergic dysfunction in human Dravet syndrome. *Epilepsia* **2018**, *59*, 2106–2117. <https://doi.org/10.1111/epi.14574>.
38. Roseti, C.; Fucile, S.; Lauro, C.; Martinello, K.; Bertollini, C.; Esposito, V.; Mascia, A.; Catalano, M.; Aronica, E.; Limatola, C.; et al. Fractalkine/CX3CL1 modulates GABAA currents in human temporal lobe epilepsy. *Epilepsia* **2013**, *54*, 1834–1844. <https://doi.org/10.1111/epi.12354>.
39. Miledi, R.; Duenas, Z.; Martinez-Torres, A.; Kawas, C.H.; Eusebi, F. Microtransplantation of functional receptors and channels from the Alzheimer's brain to frog oocytes. *Proc. Natl. Acad. Sci. USA* **2004**, *101*, 1760–1763.
40. Zwart, R.; Mazzo, F.; Sher, E. Microtransplantation of human brain receptors into oocytes to tackle key questions in drug discovery. *Drug. Discov. Today* **2019**, *24*, 533–543. <https://doi.org/10.1016/j.drudis.2018.10.015>.
41. Ruffolo, G.; Di Bonaventura, C.; Cifelli, P.; Roseti, C.; Fattouch, J.; Morano, A.; Limatola, C.; Aronica, E.; Palma, E.; Giallardo, A.T. A novel action of lacosamide on GABAA currents sets the ground for a synergic interaction with levetiracetam in treatment of epilepsy. *NeuroBiol. Dis.* **2018**, *115*, 59–68. <https://doi.org/10.1016/j.nbd.2018.03.015>.
42. Roseti, C.; van Vliet, E.A.; Cifelli, P.; Ruffolo, G.; Baayen, J.C.; Di Castro, M.A.; Bertollini, C.; Limatola, C.; Aronica, E.; Vezzani, A.; et al. GABAA currents are decreased by IL-1 β in epileptogenic tissue of patients with temporal lobe epilepsy: Implications for ictogenesis. *NeuroBiol. Dis.* **2015**, *82*, 311–320. <https://doi.org/10.1016/j.nbd.2015.07.003>.
43. Roseti, C.; Cifelli, P.; Ruffolo, G.; Barbieri, E.; Guescini, M.; Esposito, V.; Di Gennaro, G.; Limatola, C.; Giovannelli, A.; Aronica, E.; et al. Erythropoietin Increases GABA(A) Currents in Human Cortex from TLE Patients. *Neuroscience* **2020**, *439*, 153–162. <https://doi.org/10.1016/j.neuroscience.2019.04.013>.
44. Ruffolo, G.; Cifelli, P.; Miranda-Lourenço, C.; De Felice, E.; Limatola, C.; Sebastião, A.M.; Diógenes, M.J.; Aronica, E.; Palma, E. Rare Diseases of Neurodevelopment: Maintain the Mystery or Use a Dazzling Tool for Investigation? The Case of Rett Syndrome. *Neuroscience* **2020**, *439*, 146–152. <https://doi.org/10.1016/j.neuroscience.2019.06.015>.
45. Palma, E.; Reyes-Ruiz, J.M.; Lopercolo, D.; Roseti, C.; Bertollini, C.; Ruffolo, G.; Cifelli, P.; Onesti, E.; Limatola, C.; Miledi, R.; et al. Acetylcholine receptors from human muscle as pharmacological targets for ALS therapy. *Proc. Natl. Acad. Sci. USA* **2016**, *113*, 3060–3065. doi:10.1073/pnas.1600251113.
46. Giovannardi, S.; Soragna, A.; Magagnin, S.; Faravelli, L. Functional expression of type 1 rat GABA transporter in microinjected *Xenopus laevis* oocytes. *Methods Mol. Biol.* **2007**, *375*, 235–255. https://doi.org/10.1007/978-1-59745-388-2_12.
47. Dascal, N. Voltage clamp recordings from *Xenopus* oocytes. *Curr. Protoc. Neurosci.* **2001**, *10*, 6–12. <https://doi.org/10.1002/0471142301.ns0612s10>.
48. Guan, B.; Chen, X.; Zhang, H. Two-electrode voltage clamp. *Methods Mol. Biol.* **2013**, *998*, 79–89. https://doi.org/10.1007/978-1-62703-351-0_6.
49. Hediger, M.A.; Coady, M.J.; Ikeda, T.S.; Wright, E.M. Expression cloning and cDNA sequencing of the Na⁺/glucose co-transporter. *Nature* **1987**, *330*, 379–381. <https://doi.org/10.1038/330379a0>.
50. Blakely, R.D.; Robinson, M.B.; Amara, S.G. Expression of neurotransmitter transport from rat brain mRNA in *Xenopus laevis* oocytes. *Proc. Natl. Acad. Sci. USA* **1988**, *85*, 9846–9850.
51. Romero, M.F.; Kanai, Y.; Gunshin, H.; Hediger, M.A. Expression cloning using *Xenopus laevis* oocytes. *Methods Enzym.* **1998**, *296*, 17–52. [https://doi.org/10.1016/s0076-6879\(98\)96004-9](https://doi.org/10.1016/s0076-6879(98)96004-9).
52. Markovich, D. Expression cloning and radiotracer uptakes in *Xenopus laevis* oocytes. *Nature Protoc.* **2008**, *3*, 1975–1980. <https://doi.org/10.1038/nprot.2008.151>.
53. Cesar-Razquin, A.; Snijder, B.; Frappier-Brinton, T.; Isserlin, R.; Gyimesi, G.; Bai, X.; Reithmeier, R.A.; Hepworth, D.; Hediger, M.A.; Edwards, A.M.; et al. A Call for Systematic Research on Solute Carriers. *Cell* **2015**, *162*, 478–487. <https://doi.org/10.1016/j.cell.2015.07.022>.
54. Superti-Furga, G.; Lackner, D.; Wiedmer, T.; Ingles-Prieto, A.; Barbosa, B.; Girardi, E.; Goldmann, U.; Gurtl, B.; Klavins, K.; Klimek, C.; et al. The RESOLUTE consortium: Unlocking SLC transporters for drug discovery. *Nature Rev. Drug Discov.* **2020**, *19*, 429–430. <https://doi.org/10.1038/d41573-020-00056-6>.
55. Wang, W.W.; Gallo, L.; Jadhav, A.; Hawkins, R.; Parker, C.G. The Druggability of Solute Carriers. *J. Med. Chem.* **2020**, *63*, 3834–3867. <https://doi.org/10.1021/acs.jmedchem.9b01237>.

56. Kanner, B.I. Transmembrane domain I of the gamma-aminobutyric acid transporter GAT-1 plays a crucial role in the transition between cation leak and transport modes. *J. Biol. Chem.* **2003**, *278*, 3705–3712. <https://doi.org/10.1074/jbc.M210525200>.
57. Zhou, Y.G.; Bennett, E.R.; Kanner, B.I. The aqueous accessibility in the external half of transmembrane domain I of the GABA transporter GAT-1 is modulated by its Ligands. *J. Biol. Chem.* **2004**, *279*, 13800–13808. <https://doi.org/10.1074/jbc.M311579200>.
58. Yamashita, A.; Singh, S.K.; Kawate, T.; Jin, Y.; Gouaux, E. Crystal structure of a bacterial homologue of Na⁺/Cl⁻-dependent neurotransmitter transporters. *Nature* **2005**, *437*, 215–223. <https://doi.org/10.1038/Nature03978>.
59. Barker, E.L.; Blakely, R.D. Structural Determinants of Neurotransmitter Transport using Cross-Species Chimeras: Studies on Serotonine Transporter. *Methods Enzymol.* **1998**, *296*, 475–498.
60. Buck, K.J.; Amara, S.G. In Vivo Generation of chimeras. *Methods Enzymol.* **1998**, *296*, 466–475.
61. Soragna, A.; Mari, S.A.; Pisani, R.; Peres, A.; Castagna, M.; Sacchi, V.F.; Bossi, E. Structural domains involved in substrate selectivity in two neutral amino acid transporters. *Am. J. Physiol. Cell Physiol.* **2004**, *287*, C754–761. <https://doi.org/10.1152/ajp-cell.00016.2004>.
62. Buck, K.J.; Amara, S.G. Chimeric dopamine-norepinephrine transporters delineate structural domains influencing selectivity for catecholamines and 1-methyl-4-phenylpyridinium. *Proc. Natl. Acad. Sci. USA* **1994**, *91*, 12584–12588. <https://doi.org/10.1073/pnas.91.26.12584>.
63. Buck, K.J.; Amara, S.G. Structural domains of catecholamine transporter chimeras involved in selective inhibition by antidepressants and psychomotor stimulants. *Mol. Pharmacol.* **1995**, *48*, 1030–1037.
64. Buracco, S.; Peracino, B.; Cinquetti, R.; Signorello, E.; Vollero, A.; Imperiali, F.; Castagna, M.; Bossi, E.; Bozzaro, S. Dictyostelium Nrp1, which is structurally and functionally similar to mammalian DMT1 transporter, mediates phagosomal iron efflux. *J. Cell Sci.* **2015**, *128*, 3304–3316. <https://doi.org/10.1242/jcs.173153>.
65. Sacher, A.; Cohen, A.; Nelson, N. Properties of the mammalian and yeast metal-ion transporters DCT1 and Smf1p expressed in *Xenopus laevis* oocytes. *J. Exp. Biol.* **2001**, *204*, 1053–1061.
66. Bacconi, A.; Virkki, L.V.; Biber, J.; Murer, H.; Forster, I.C. Renouncing electroneutrality is not free of charge: Switching on electrogenicity in a Na⁺-coupled phosphate cotransporter. *Proc. Natl. Acad. Sci. USA* **2005**, *102*, 12606–12611.
67. Castagna, M.; Cinquetti, R.; Verri, T.; Vacca, F.; Giovanola, M.; Barca, A.; Romanazzi, T.; Roseti, C.; Galli, A.; Bossi, E. The Lepidopteran KAAT1 and CAATCH1: Orthologs to Understand Structure-Function Relationships in Mammalian SLC6 Transporters. *Neurochem. Res.* **2022**, *47*, 111–126. <https://doi.org/10.1007/s11064-021-03410-1>.
68. Margheritis, E.; Terova, G.; Oyadeyi, A.S.; Renna, M.D.; Cinquetti, R.; Peres, A.; Bossi, E. Characterization of the transport of lysine-containing dipeptides by PepT1 orthologs expressed in *Xenopus laevis* oocytes. *Comp. Biochem. Physiology. Part A Mol. Integr. Physiol.* **2013**, *164*, 520–528. <https://doi.org/10.1016/j.cbpa.2012.12.016>.
69. Giovanola, M.; D'Antoni, F.; Santacroce, M.; Mari, S.A.; Cherubino, F.; Bossi, E.; Sacchi, V.F.; Castagna, M. Role of a conserved glycine triplet in the NSS amino acid transporter KAAT1. *Biochim. Biophys. Acta* **2012**, *1818*, 1737–1744. <https://doi.org/10.1016/j.bbamem.2012.02.023>.
70. Castagna, M.; Bossi, E.; Sacchi, V.F. Molecular physiology of the insect K-activated amino acid transporter 1 (KAAT1) and cation-anion activated amino acid transporter/channel 1 (CAATCH1) in the light of the structure of the homologous protein LeuT. *Insect Mol. Biol.* **2009**, *18*, 265–279. <https://doi.org/10.1111/j.1365-2583.2009.00881.x>.
71. Giovanola, M.; Vollero, A.; Cinquetti, R.; Bossi, E.; Forrest, L.R.; Di Cairano, E.S.; Castagna, M. Threonine 67 is a key component in the coupling of the NSS amino acid transporter KAAT1. *Biochim. Biophys. Acta Biomembr.* **2018**, *1860*, 1179–1186. <https://doi.org/10.1016/j.bbamem.2018.01.020>.
72. Mari, S.A.; Soragna, A.; Castagna, M.; Bossi, E.; Peres, A.; Sacchi, V.F. Aspartate 338 contributes to the cationic specificity and to driver-amino acid coupling in the insect cotransporter KAAT1. *Cell Mol. Life Sci.* **2004**, *61*, 243–256.
73. Cao, Y.; Li, M.; Mager, S.; Lester, H.A. Amino acid residues that control pH modulation of transport-associated current in mammalian serotonin transporters. *J. Neurosci.* **1998**, *18*, 7739–7749.
74. Kohler, K.; Forster, I.C.; Stange, G.; Biber, J.; Murer, H. Essential cysteine residues of the type IIa Na⁺/Pi cotransporter. *Pflug. Arch.* **2003**, *446*, 203–210.
75. Ehnes, C.; Forster, I.C.; Bacconi, A.; Kohler, K.; Biber, J.; Murer, H. Structure-function relations of the first and fourth extracellular linkers of the type IIa Na⁺/Pi cotransporter: II. Substrate interaction and voltage dependency of two functionally important sites. *J. Gen. Physiol.* **2004**, *124*, 489–503.
76. Ehnes, C.; Forster, I.C.; Kohler, K.; Bacconi, A.; Stange, G.; Biber, J.; Murer, H. Structure-function relations of the first and fourth predicted extracellular linkers of the type IIa Na⁺/Pi cotransporter: I. Cysteine scanning mutagenesis. *J. Gen. Physiol.* **2004**, *124*, 475–488.
77. Misznier, A.; Peres, A.; Castagna, M.; Bette, S.; Giovannardi, S.; Cherubino, F.; Bossi, E. Structural and functional basis of amino acid specificity in the invertebrate cotransporter KAAT1. *J. Physiol.* **2007**, *581*, 899–913. <https://doi.org/10.1113/jphysiol.2007.132555>.
78. Vandenberg, R.J.; Shaddick, K.; Ju, P. Molecular basis for substrate discrimination by glycine transporters. *J. Biol. Chem.* **2007**, *282*, 14447–14453. <https://doi.org/10.1074/jbc.M609158200>.
79. Ben Yona, A.; Bendahan, A.; Kanner, B.I. A glutamine residue conserved in the neurotransmitter:Sodium:Symporters is essential for the interaction of chloride with the GABA transporter GAT-1. *J. Biol. Chem.* **2010**.

80. Forrest, L.R.; Tavoulari, S.; Zhang, Y.W.; Rudnick, G.; Honig, B. Identification of a chloride ion binding site in Na⁺/Cl⁻-dependent transporters. *Proc. Natl. Acad. Sci. USA* **2007**, *104*, 12761–12766.
81. Mari, S.A.; Soragna, A.; Castagna, M.; Santacroce, M.; Perego, C.; Bossi, E.; Peres, A.; Sacchi, V.F. Role of the conserved glutamine 291 in the rat gamma-aminobutyric acid transporter rGAT-1. *Cell Mol. Life Sci.* **2006**, *63*, 100–111.
82. Perez-Siles, G.; Nunez, E.; Morreale, A.; Jimenez, E.; Leo-Macias, A.; Pita, G.; Cherubino, F.; Sangaletti, R.; Bossi, E.; Ortiz, A.R.; et al. An aspartate residue in the external vestibule of glycine transporter 2 (GLYT2) controls cation access and transport coupling. *Biochem. J.* **2011**, *442*, 323–334.
83. Edelheit, O.; Hanukoglu, A.; Hanukoglu, I. Simple and efficient site-directed mutagenesis using two single-primer reactions in parallel to generate mutants for protein structure-function studies. *BMC Biotechnol.* **2009**, *9*, 61. <https://doi.org/10.1186/1472-6750-9-61>.
84. Ishii, T.M.; Zerr, P.; Xia, X.-M.; Bond, C.T.; Maylie, J.; Adelman, J.P. [4] Site-directed mutagenesis. In *Methods in Enzymology*; Academic Press: 1998; Volume 293, pp. 53–71.
85. Forlani, G.; Bossi, E.; Ghirardelli, R.; Giovannardi, S.; Binda, F.; Bonadiman, L.; Ielmini, L.; Peres, A. Mutation K448E in the external loop 5 of rat GABA transporter rGAT1 induces pH sensitivity and alters substrate interactions. *J. Physiol.* **2001**, *536*, 479–494.
86. Mager, S.; Naeve, J.; Quick, M.; Labarca, C.; Davidson, N.; Lester, H.A. Steady states, charge movements, and rates for a cloned GABA transporter expressed in *Xenopus* oocytes. *Neuron* **1993**, *10*, 177–188. [https://doi.org/10.1016/0896-6273\(93\)90309-f](https://doi.org/10.1016/0896-6273(93)90309-f).
87. Lester, H.A.; Cao, Y.; Mager, S. Listening to neurotransmitter transporters. *Neuron* **1996**, *17*, 807–810.
88. Mager, S.; KleinbergerDoron, N.; Keshet, G.I.; Davidson, N.; Kanner, B.I.; Lester, H.A. Ion binding and permeation at the GABA transporter GAT1. *J. Neurosci.* **1996**, *16*, 5405–5414.
89. Parent, L.; Supplisson, S.; Loo, D.D.; Wright, E.M. Electrogenic properties of the cloned Na⁺/glucose cotransporter: II—A transport model under nonrapid equilibrium conditions. *J. Membr. Biol.* **1992**, *125*, 63–79.
90. Sacher, A.; Nelson, N.; Ogi, J.T.; Wright, E.M.; Loo, D.D.; Eskandari, S. Pre-Steady state and Steady-State Kinetics and Turnover Rate of Mouse g-Aminobutyric Acid Transporter (mGAT3). *J. Membr. Biol.* **2002**, *190*, 57–73.
91. Sala-Rabanal, M.; Loo, D.D.; Hirayama, B.A.; Wright, E.M. Molecular mechanism of dipeptide and drug transport by the human renal H⁺/oligopeptide cotransporter hPEPT2. *Am. J. Physiol. Ren. Physiol.* **2008**, *294*, F1422–F1432.
92. Binda, F.; Bossi, E.; Giovannardi, S.; Forlani, G.; Peres, A. Temperature effects on the presteady-state and transport-associated currents of GABA cotransporter rGAT1. *FEBS Lett.* **2002**, *512*, 303–307.
93. Peres, A.; Giovannardi, S.; Bossi, E.; Fesce, R. Electrophysiological insights into the mechanism of ion-coupled cotransporters. *N. Physiol. Sci.* **2004**, *19*, 80–84.
94. Renna, M.D.; Sangaletti, R.; Bossi, E.; Cherubino, F.; Kottra, G.; Peres, A. Unified modeling of the mammalian and fish proton-dependent oligopeptide transporter PepT1. *Channels* **2011**, *5*, 89–99.
95. Bossi, E.; Cherubino, F.; Margheritis, E.; Oyadeyi, A.S.; Vollero, A.; Peres, A. Temperature effects on the kinetic properties of the rabbit intestinal oligopeptide cotransporter PepT1. *Pflug. Arch.* **2012**, *464*, 183–191.
96. Vacca, F.; Gomes, A.S.; Murashita, K.; Cinquetti, R.; Roseti, C.; Barca, A.; Rønnestad, I.; Verri, T.; Bossi, E. Functional characterization of Atlantic salmon (*Salmo salar* L.) PepT2 transporters. *J. Physiol.* **2022**, *600*, 2377–2400. <https://doi.org/10.1113/jp282781>.
97. Sangaletti, R.; Terova, G.; Peres, A.; Bossi, E.; Cora, S.; Saroglia, M. Functional expression of the oligopeptide transporter PepT1 from the sea bass (*Dicentrarchus labrax*). *Pflug. Arch. Eur. J. Physiol.* **2009**, *459*, 47–54. <https://doi.org/10.1007/s00424-009-0700-0>.
98. Fesce, R.; Giovannardi, S.; Binda, F.; Bossi, E.; Peres, A. The relation between charge movement and transport-associated currents in the rat GABA cotransporter rGAT1. *J. Physiol.* **2002**, *545*, 739–750.
99. Loo, D.D.; Hazama, A.; Supplisson, S.; Turk, E.; Wright, E.M. Relaxation kinetics of the Na⁺/glucose cotransporter. *Proc. Natl. Acad. Sci. USA* **1993**, *90*, 5767–5771. <https://doi.org/10.1073/pnas.90.12.5767>.
100. Sala-Rabanal, M.; Loo, D.D.; Hirayama, B.A.; Turk, E.; Wright, E.M. Molecular interactions between dipeptides, drugs and the human intestinal H⁺-oligopeptide cotransporter hPEPT1. *J. Physiol.* **2006**, *574*, 149–166.
101. Forster, I.C. The molecular mechanism of SLC34 proteins: Insights from two decades of transport assays and structure-function studies. *Pflug. Arch. Eur. J. Physiol.* **2019**, *471*, 15–42. <https://doi.org/10.1007/s00424-018-2207-z>.
102. Peres, A.; Vollero, A.; Margheritis, E.; D'Antoni, F.; Bossi, E. An Inverse Relationship Links Temperature and Substrate Apparent Affinity in the Ion-Coupled Cotransporters rGAT1 and KAAT1. *Int. J. Mol. Sci.* **2012**, *13*, 15565–15574.
103. Rizzello, A.; Romano, A.; Kottra, G.; Acierio, R.; Storelli, C.; Verri, T.; Daniel, H.; Maffia, M. Protein cold adaptation strategy via a unique seven-amino acid domain in the icefish (*Chionodraco hamatus*) PEPT1 transporter. *Proc. Natl. Acad. Sci. USA* **2013**, *110*, 7068–7073.
104. Bacconi, A.; Ravera, S.; Virkki, L.V.; Murer, H.; Forster, I.C. Temperature dependence of steady-state and presteady-state kinetics of a type IIb Na⁺/Pⁱ cotransporter. *J. Membr. Biol.* **2007**, *215*, 81–92.
105. Margheritis, E.; Imperiali, F.G.; Cinquetti, R.; Vollero, A.; Terova, G.; Rimoldi, S.; Girardello, R.; Bossi, E. Amino acid transporter B(0)AT1 (slc6a19) and ancillary protein: Impact on function. *Pflug. Arch. Eur. J. Physiol.* **2016**, *468*, 1363–1374. <https://doi.org/10.1007/s00424-016-1842-5>.

106. Fairweather, S.J.; Broer, A.; Subramanian, N.; Tumer, E.; Cheng, Q.; Schmoll, D.; O'Mara, M.L.; Broer, S. Molecular basis for the interaction of the mammalian amino acid transporters B0AT1 and B0AT3 with their ancillary protein collectrin. *J. Biol. Chem.* **2015**, *290*, 24308–24325. <https://doi.org/10.1074/jbc.M115.648519>.
107. Cherubino, F.; Bertram, S.; Bossi, E.; Peres, A. Pre-steady-state and reverse transport currents in the GABA transporter GAT1. *Am J. Physiol. Cell Physiol.* **2012**, *302*, C1096–1108. <https://doi.org/10.1152/ajpcell.00268.2011>.
108. Bertram, S.; Cherubino, F.; Bossi, E.; Castagna, M.; Peres, A. Gaba reverse transport by the neuronal cotransporter gat1: Influence of internal chloride depletion. *Am. J. Physiol. Cell Physiol.* **2011**, *301*, C1064–C1073.
109. Kottra, G.; Stamford, A.; Daniel, H. PEPT1 as a paradigm for membrane carriers that mediate electrogenic bidirectional transport of anionic, cationic, and neutral substrates. *J. Biol. Chem.* **2002**, *277*, 32683–32691.
110. Song, L.; Mercado, A.; Vazquez, N.; Xie, Q.; Desai, R.; George, A.L., Jr.; Gamba, G.; Mount, D.B. Molecular, functional, and genomic characterization of human KCC2, the neuronal K-Cl cotransporter. *Brain Res. Mol. Brain Res.* **2002**, *103*, 91–105.
111. Sugiyama, H.; Ito, I.; Hirono, C. A new type of glutamate receptor linked to inositol phospholipid metabolism. *Nature* **1987**, *325*, 531–533. <https://doi.org/10.1038/325531a0>.
112. Pin, J.P.; Waeber, C.; Prezeau, L.; Bockaert, J.; Heinemann, S.F. Alternative splicing generates metabotropic glutamate receptors inducing different patterns of calcium release in *Xenopus* oocytes. *Proc. Natl. Acad. Sci. USA* **1992**, *89*, 10331–10335. <https://doi.org/10.1073/pnas.89.21.10331>.
113. Lechleiter, J.; Hellmiss, R.; Duerson, K.; Ennulat, D.; David, N.; Clapham, D.; Peralta, E. Distinct sequence elements control the specificity of G protein activation by muscarinic acetylcholine receptor subtypes. *Embo J.* **1990**, *9*, 4381–4390. <https://doi.org/10.1002/j.1460-2075.1990.tb07888.x>.
114. Courjaret, R.; Machaca, K. *Xenopus* Oocyte As a Model System to Study Store-Operated Ca²⁺ Entry (SOCE). *Front. Cell Dev. Biol.* **2016**, *4*, 66. <https://doi.org/10.3389/fcell.2016.00066>.
115. Priest, M.; Bezanilla, F. Functional Site-Directed Fluorometry. *Adv. Exp. Med. Biol.* **2015**, *869*, 55–76. https://doi.org/10.1007/978-1-4939-2845-3_4.
116. Virkki, L.V.; Murer, H.; Forster, I.C. Voltage clamp fluorometric measurements on a type II Na⁺-coupled Pi cotransporter: Shedding light on substrate binding order. *J. Gen. Physiol.* **2006**, *127*, 539–555.
117. Treger, J.S.; Priest, M.F.; Bezanilla, F. Single-molecule fluorimetry and gating currents inspire an improved optical voltage indicator. *eLife* **2015**, *4*, e10482. <https://doi.org/10.7554/eLife.10482>.
118. Horne, A.J.; Fedida, D. Use of voltage clamp fluorimetry in understanding potassium channel gating: A review of Shaker fluorescence data. *Can. J. Physiol. Pharmacol.* **2009**, *87*, 411–418. <https://doi.org/10.1139/y09-024>.
119. Kalstrup, T.; Blunck, R. Voltage-clamp Fluorometry in *Xenopus* Oocytes Using Fluorescent Unnatural Amino Acids. *J. Vis. Exp. JoVE* **2017**, *27*, e55598. <https://doi.org/10.3791/55598>.
120. Toft-Bertelsen, T.L.; Krizaj, D.; MacAulay, N. When size matters: Transient receptor potential vanilloid 4 channel as a volume-sensor rather than an osmo-sensor. *J. Physiol.* **2017**, *595*, 3287–3302. <https://doi.org/10.1113/jp274135>.
121. Iovino, L.; Giusti, V.; Pischedda, F.; Giusto, E.; Plotegher, N.; Marte, A.; Battisti, I.; Di Iacovo, A.; Marku, A.; Piccoli, G.; et al. Trafficking of the glutamate transporter is impaired in LRRK2-related Parkinson's disease. *Acta Neuropathol.* **2022**, *144*, 81–106. <https://doi.org/10.1007/s00401-022-02437-0>.
122. Bossi, E.; Renna, M.D.; Sangaletti, R.; D'Antoni, F.; Cherubino, F.; Kottra, G.; Peres, A. Residues R282 and D341 act as electrostatic gates in the proton-dependent oligopeptide transporter PepT1. *J. Physiol.* **2011**, *589*, 495–510.
123. Lin-Moshier, Y.; Marchant, J.S. A rapid Western blotting protocol for the *Xenopus* oocyte. *Cold Spring Harb. Protoc.* **2013**, *2013*, pdb-prot072793. <https://doi.org/10.1101/pdb.prot072793>.
124. Blumenstein, Y.; Ivanina, T.; Shistik, E.; Bossi, E.; Peres, A.; Dascal, N. Regulation of cardiac L-type Ca²⁺ channel by coexpression of G(α_s) in *Xenopus* oocytes. *FEBS Lett.* **1999**, *444*, 78–84.
125. Ivanina, T.; Perets, T.; Thornhill, W.B.; Levin, G.; Dascal, N.; Lotan, I. Phosphorylation by protein kinase A of RCK1 K⁺ channels expressed in *Xenopus* oocytes. *Biochemistry* **1994**, *33*, 8786–8792.
126. Jørgensen, M.E.; Nour-Eldin, H.H.; Halkier, B.A. A Western Blot Protocol for Detection of Proteins Heterologously Expressed in *Xenopus laevis* Oocytes. *Methods Mol. Biol.* **2016**, *1405*, 99–107. https://doi.org/10.1007/978-1-4939-3393-8_10.
127. Schwappach, B.; Zerangue, N.; Jan, Y.N.; Jan, L.Y. Molecular Basis for KATP Assembly: Transmembrane Interactions Mediate Association of a K⁺ Channel with an ABC Transporter. *Neuron* **2000**, *26*, 155–167. [https://doi.org/10.1016/S0896-6273\(00\)81146-0](https://doi.org/10.1016/S0896-6273(00)81146-0).
128. Mertl, M.; Daniel, H.; Kottra, G. Substrate-induced changes in the density of peptide transporter PEPT1 expressed in *Xenopus* oocytes. *Am.J.Physiol. Cell Physiol.* **2008**, *295*, C1332–C1343. <https://doi.org/10.1152/ajpcell.00241.2008>.
129. Kottra, G.; Spanier, B.; Verri, T.; Daniel, H. Peptide transporter isoforms are discriminated by the fluorophore-conjugated dipeptides beta-Ala- and d-Ala-Lys-N-7-amino-4-methylcoumarin-3-acetic acid. *Physiol. Rep.* **2013**, *1*, e00165. <https://doi.org/10.1002/phy2.165>.
130. Illing, A.C.; Shawki, A.; Cunningham, C.L.; Mackenzie, B. Substrate profile and metal-ion selectivity of human divalent metal-ion transporter-1. *J. Biol. Chem.* **2012**, *287*, 30485–30496. <https://doi.org/10.1074/jbc.M112.364208>.

131. Musa-Aziz, R.; Boron, W.F.; Parker, M.D. Using fluorometry and ion-sensitive microelectrodes to study the functional expression of heterologously-expressed ion channels and transporters in *Xenopus* oocytes. *Methods* **2010**, *51*, 134–145. <https://doi.org/10.1016/j.ymeth.2009.12.012>.
132. Bossi, E.; Zanella, D.; Gornati, R.; Bernardini, G. Cobalt oxide nanoparticles can enter inside the cells by crossing plasma membranes. *Sci. Rep.* **2016**, *6*, 22254. <https://doi.org/10.1038/srep22254>.
133. Zanella, D.; Bossi, E.; Gornati, R.; Faria, N.; Powell, J.; Bernardini, G. The direct permeation of nanoparticles through the plasma membrane transiently modifies its properties. *Biochim. Biophys. Acta Biomembr.* **2019**, *1861*, 182997. <https://doi.org/10.1016/j.bbamem.2019.05.019>.
134. Zanella, D.; Bossi, E.; Gornati, R.; Bastos, C.; Faria, N.; Bernardini, G. Iron oxide nanoparticles can cross plasma membranes. *Sci. Rep.* **2017**, *7*, 11413.
135. Cinquetti, R.; Imperiali, F.G.; Bozzaro, S.; Zanella, D.; Vacca, F.; Roseti, C.; Peracino, B.; Castagna, M.; Bossi, E. Characterization of Transport Activity of SLC11 Transporters in *Xenopus laevis* Oocytes by Fluorophore Quenching. *SLAS Discov.* **2021**, *26*, 798–810. <https://doi.org/10.1177/24725552211004123>.
136. Lee, E.E.L.; Bezanilla, F. Methodological improvements for fluorescence recordings in *Xenopus laevis* oocytes. *J. Gen. Physiol.* **2019**, *151*, 264–272. <https://doi.org/10.1085/jgp.201812189>.
137. Meredith, D.; Boyd, C.A. Dipeptide transport characteristics of the apical membrane of rat lung type II pneumocytes. *Am. J. Physiol.* **1995**, *269*, L137–L143. <https://doi.org/10.1152/ajplung.1995.269.2.L137>.
138. Fairweather, S.J.; Okada, S.; Gauthier-Coles, G.; Javed, K.; Bröer, A.; Bröer, S. A GC-MS/Single-Cell Method to Evaluate Membrane Transporter Substrate Specificity and Signaling. *Front. Mol. Biosci.* **2021**, *8*, 646574. <https://doi.org/10.3389/fmolb.2021.646574>.
139. Vollero, A.; Imperiali, F.G.; Cinquetti, R.; Margheritis, E.; Peres, A.; Bossi, E. The D-amino acid transport by the invertebrate SLC6 transporters KAAT1 and CAATCH1 from *Manduca sexta*. *Physiol. Rep.* **2016**, *4*, e12691. <https://doi.org/10.14814/phy2.12691>.
140. Trumbull, J.D.; Maslana, E.S.; McKenna, D.G.; Nemcek, T.A.; Niforatos, W.; Pan, J.Y.; Parihar, A.S.; Shieh, C.C.; Wilkins, J.A.; Briggs, C.A.; et al. High throughput electrophysiology using a fully automated, multiplexed recording system. *Recept. Channels* **2003**, *9*, 19–28.
141. Malysz, J.; Grønlien, J.H.; Timmermann, D.B.; Håkerud, M.; Thorin-Hagene, K.; Ween, H.; Trumbull, J.D.; Xiong, Y.; Briggs, C.A.; Ahning, P.K.; et al. Evaluation of $\alpha 7$ Nicotinic Acetylcholine Receptor Agonists and Positive Allosteric Modulators Using the Parallel Oocyte Electrophysiology Test Station. *ASSAY Drug Dev. Technol.* **2009**, *7*, 374–390. <https://doi.org/10.1089/adt.2009.0194>.
142. Shieh, C.C.; Trumbull, J.D.; Sarthy, J.F.; McKenna, D.G.; Parihar, A.S.; Zhang, X.F.; Faltynek, C.R.; Gopalakrishnan, M. Automated Parallel Oocyte Electrophysiology Test station (POETs): A screening platform for identification of ligand-gated ion channel modulators. *Assay Drug Dev. Technol.* **2003**, *1*, 655–663. <https://doi.org/10.1089/154065803770381011>.
143. Barth, D.; Fronius, M. Shear force modulates the activity of acid-sensing ion channels at low pH or in the presence of non-proton ligands. *Sci. Rep.* **2019**, *9*, 6781. <https://doi.org/10.1038/s41598-019-43097-7>.
144. Liman, E.R.; Tytgat, J.; Hess, P. Subunit stoichiometry of a mammalian K⁺ channel determined by construction of multimeric cDNAs. *Neuron* **1992**, *9*, 861–871. [https://doi.org/10.1016/0896-6273\(92\)90239-a](https://doi.org/10.1016/0896-6273(92)90239-a).
145. Trudeau, M.C.; Warmke, J.W.; Ganetzky, B.; Robertson, G.A. HERG, a human inward rectifier in the voltage-gated potassium channel family. *Science* **1995**, *269*, 92–95. <https://doi.org/10.1126/science.7604285>.
146. Nowak, M.W.; Gallivan, J.P.; Silverman, S.K.; Labarca, C.; Daugherty, D.A.; Lester, H.A. In Vivo Incorporation of Unnatural Amino Acids into Ion Channels in *Xenopus* Oocytes Expression System. *Methods Enzymol.* **1998**, *293*, 504–529.
147. Ludewig, U.; von Wiren, N.; Frommer, W.B. Uniport of NH₄⁺ by the root hair plasma membrane ammonium transporter LeAMT1; 1. *J. Biol. Chem.* **2002**, *277*, 13548–13555.
148. Fairweather, S.J.; Broer, A.; O'Mara, M.L.; Broer, S. Intestinal Peptidases Form Functional Complexes with Neutral Amino Acid Transporter B0AT1. *Biochem. J.* **2012**, *446*, 135–148.